Intradiscal linezolid (PP353) treatment for chronic low back pain associated with Modic change type 1: an international, first-in-human, randomised, sham procedure-controlled, double-blind, phase 1b clinical trial

20261 citationsJournal Articlegold Open Access

Authors

Michael R. Lassen · Gentofte Hospital

Matthew Scarborough · Nuffield Orthopaedic Centre

Nigel Gilchrist · Christchurch Clinical Studies Trust

Shiva S. Tripathi · Lancashire Teaching Hospitals NHS Foundation Trust

Cathy Price · Isle of Wight NHS Trust

A. Horcajadas · Complejo Hospitalario Universitario de Granada

Javier DeAndres

Abstract

Persica Pharmaceuticals Ltd funded the trial and was responsible for the conceptualisation, overall design, collation of data, decision to publish and the first draft of the manuscript.

Topics & Keywords

Spine and Intervertebral Disc Pathology Musculoskeletal pain and rehabilitation Vitamin K Research Studies

Publication Details

Published in: EClinicalMedicine

Volume 92, pp. 103764-103764

DOI: 10.1016/j.eclinm.2026.103764

Field-Weighted Citation Impact: 38.80

Command Palette

Intradiscal linezolid (PP353) treatment for chronic low back pain associated with Modic change type 1: an international, first-in-human, randomised, sham procedure-controlled, double-blind, phase 1b clinical trial

Authors

Abstract

Topics & Keywords

Publication Details